



**Biocon Limited**

20th KM Hosur Road  
Electronics City  
Bangalore 560 100, India  
T 91 80 2808 2808  
F 91 80 2852 3423  
CIN : L24234KA1978PLC003417

[www.biocon.com](http://www.biocon.com)

2018/SEC/APRIL/316

April 11, 2018

National Stock Exchange of India Limited  
"Exchange Plaza", 5<sup>th</sup> Floor,  
Plot No. C/1, G Block,  
Bandra-Kurla Complex  
Bandra (East), Mumbai – 400051

BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai – 400001

NSE - Symbol - BIOCON

BSE - Scrip code - 532523

Dear Sir,

**Sub: Mylan and Biocon seek to accelerate introduction of adalimumab biosimilar in EU**

In compliance with the provisions of regulation 30 of SEBI (Listing Obligations and Disclosure Requirement) Regulations 2015, please find below the Company's statement on the subject matter.

"Mylan and Biocon have agreed to accelerate introduction of adalimumab biosimilar in Europe through Mylan's in-licensing arrangement with Fujifilm Kyowa Kirin Biologics (FKB). FKB's product is at an advanced stage of review and could potentially obtain approval in Europe in the second half of 2018. We believe that through this arrangement, Mylan could commercialize FKB's Adalimumab in EU around market formation. Biocon retains its economic interest in this arrangement vis-a-vis Mylan in line with its existing global collaboration with Mylan for monoclonal antibodies". – Biocon Spokesperson

Kindly take on record the same.

Thanking You,

For **BIOCON LIMITED**

**(President – Finance and Chief Financial Officer)**